New drug FOG-001 takes on Hard-to-Treat cancers

NCT ID NCT05919264

Recruiting now Disease control Sponsor: Parabilis Medicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOG-001 (a drug given intravenously, sometimes combined with chemotherapy or other cancer drugs)
What this could lead to: If it works, this could point toward a new treatment option for several types of advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. There is no guarantee the drug will work or be safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adamantinous craniopharyngioma Adenomatous Polyposis Coli cancer castration-resistant prostate carcinoma classic familial adenomatous polyposis colorectal cancer colorectal carcinoma colorectal neoplasm craniopharyngioma desmoid tumor endometrial carcinoma endometrium neoplasm familial adenomatous polyposis 1 hepatocellular carcinoma Lynch syndrome metastatic malignant neoplasm metastatic prostate carcinoma neoplasm Neoplasm Metastasis prostate cancer severe intellectual disability-progressive spastic diplegia syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADAMANTINOMATOUS CRANIOPHARYNGIOMA ADENOMATOUS POLYPOSIS COLI APC BETA-CATENIN CANCER COLORECTAL CANCER CTNNB1 DESMOID ENDOMETRIAL CARCINOMA FAMILIAL ADENOMATOUS POLYPOSIS (FAP) FAP HCC LOCALLY ADVANCED SOLID TUMOR METASTATIC CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MICROSATELLITE INSTABILITY-HIGH COLORECTAL CANCER MICROSATELLITE STABLE COLORECTAL CANCER PROSTATE CANCER SOLID TUMOR WNT PATHWAY Β-CATENIN

Contacts and locations

Locations

Arizona Cancer Center at University of Arizona
RECRUITING

Tucson, Arizona, 85719, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University
RECRUITING

Durham, North Carolina, 27705, United States
Florida Cancer Specialists
TERMINATED

Lake Mary, Florida, 32746, United States
Honor Health
RECRUITING

Scottsdale, Arizona, 85258, United States
Integrated Clinical Oncology Network (ICON)
RECRUITING

South Brisbane, Queensland, 4101, Australia
Johns Hopkins University, Sibley Memorial Hospital
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States
M Health Fairview University of Minnesota Medical Center
RECRUITING

Minneapolis, Minnesota, 55455, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarcoma Oncology Center
RECRUITING

Santa Monica, California, 90403, United States
South Texas Accelerated Research Therapeutics, LLC
RECRUITING

San Antonio, Texas, 78229, United States
Stanford Cancer Institute, Stanford University
RECRUITING

Palo Alto, California, 94304, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University Hospitals Cleveland Medical Center, Seidman Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94158, United States
University of California, Los Angeles (UCLA)
RECRUITING

Los Angeles, California, 90095, United States
University of Colorado
RECRUITING

Aurora, Colorado, 80045, United States
University of Pennsylvania, Perelman School of Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Medical Center, Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22908, United States
University of Wisconsin, Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53705, United States
Vanderbilt Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Yale University School of Medicine
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.